New chemical Entity Registered ( )

Size: px
Start display at page:

Download "New chemical Entity Registered ( )"

Transcription

1 N# Product Name Registration Date )ل ف ) 1 Dosage form Strength Active Ingredient Marketing Authorization Holder 1 pegus 25/5/2005 tab 200 Ribavarin Shawi Roche 2 Velcade 7/7/2005 vial 3.5 bortezomib mina Janssen cilag 3 19/7/2005 Avastin Vial 100 Bevacizumab roche 4 Aranesp 18/8/2005 PFS 100mcg Darbepoetin alfa Adatco Aen 5 Abilify 15 19/9/2005 tab 15 Aripiprazole Orient Bristol Myers 6 Norprolac 75mcg 19/9/2005 tab 75mcg Quinagolide Petra drug store Ferring GmbH 7 27/11/2005 Lab 3 M Aldara 5% cream 5% imiquimod Khraim drug Store Santé/France 8 23/11/2005 Gemifloxacin Factive tab 320 mesylate Hikma Hikma 9 15/12/2005 Solifenacin Vesicare tab 10 succinate Ibn rushd Yamanoushi 10 Mycamine 10/5/2005 Vial 50 Micafungin sodium Hikma Hikma 11 3/1/2006 Eye drops Relestat solution 0.05% Epinastine Arab & Agricultura Allergen 12 Strattera 5 /2/ 2006 cap Atomoxetine Arab Drug store Eli Lilly 13 Protelos 12 /2/ 2006 powder 2gm Strontium Ranelate Jordan Les lab servier 14 Certican 19 /2/ 2006 tab 1 Everolimus Jordan Novartis pharma 15 Xoliar 21/3/2006 Inj Omalizumab Jordan Novartis pharma 16 Lyrica 5 /4/ 2006 cap 25 Pregabalin Alsabbagh Pfizer 17 9 /5/ 2006 Powder for conc Alimta for sol for infusion 25/ml Pemetrexed Arab Drug store Eli Lilly /5/ 2006 Sol for inj in Apidra vial 100IU/ml Insulin glulisine Ulfa Aventis Pharma

2 19 Levemir penfill 5 /6/ 2006 Sol for inj 100IU/ml Insulin detemir Khoury NovoNnordisk 20 Exjade 20 /6/ 2006 Dispersible tab 250 deferasirox Jordan Novartis pharma /7/ 2006 Methylphenidate ncerta tab 36 HCl Ninos Janssen cilag /8/ 2006 nc for sol for Mabcampath infusion 30/ml Alemtuzumab Jordan drug store Schering AG 23 19/12/2006 nc for sol for Aldurazyme infusion 100IU/ml laronidase الزراعية Genzyme /1/ 2007 Duloxetine Hcl 60 Eli Lilly Export Cymbalta CAP 60 The Arab S.A /1/ 2007 Oxcarbazepine 60 Trileptal tab 300 /ml 26 Baraclude tab 18 /1/ 2007 tab 1 Entecavir Orient 27 Meiact tab 14 /2/ 2007 Tab 200 Cefditoren Sukhtian Tabuk 28 Zymar 28 /3/ 2007 Opth. solu 0.3% Gatifloxacin الزراعية Allergen /7/ 2007 Les Laboratories Procoralan TAB 5 Ivabradine 5 Servier /8/ 2007 Carbetocin 100 Pabal INJE 100 ug/ml ug/ml Petra Ferring GmbH /9/ %,40 Timolol 0.50 %, Duotrav EAR Drop ug Travaprost 40 Modern Alcon-uvreur 32 2 /10/ 2007 Ranibizumab 10 Lucentis SOLU 10 /ml /ml 33 Champix /10/ 2007 TAB 0.5 Varenicline 0.5 Sabbagh Pfizer 34 18/11/ 2007 Telbivudine 600 Sebivo TAB /2/ 2008 Loteprednol Bausch & Lomb Lotemax SUSP 0.5 % Etabonate 0.5 % Petra Incorporated

3 36 28 /2/ 2008 Cladribine 10 Litak VIAL 10 /5ml /5ml Al Wafi Lipomed AG /3/ 2008 Meropenem Meronem 1gm inj 1 gm Trihydrate 1 gm AstraZeneca 38 Invega Extended Release 9 /4/ 2008 TAB 6 Paliperidone 6 Telegraph Janssen Cilag /4/ 2008 ORIENT DRUG Bristol Myers Sprycel 20 TAB 20 Dasatinib 20 STORE CO Squibb /4/ 2008 Mitiglinide Glufast TAB 5 Calcium Hydrate5 Hikma Pharmaceuticals Hikma Pharmaceuticals /5/ 2008 Suleiman Tannous & Relenza tab 5 Zanamivir 5 Sons. Ltd GSK /5/ 2008 Levobupicacaine Walid Al Turk Drug Chirocaine Amp Amp 2.5 /ml Hcl 2.5/ml Store Abbott /7/ 2008 Memantine Hcl 10 Abu Sharef Medical H-Lundbeck A/S Ebixa TAB 10 Stors overseas 44 4 /8/ /15m Natalizumab 300 Tysabri SOLU l /15ml Adatco Elan Pharma /8/ 2008 Adefovir Dipivoxil Suleiman Tannous & Hepsera TAB Sons. Ltd GlaxoWellcome 46 2 /9/ 2008 Sorafenib Tosyllate Nexavar TAB Khoury Bayer AG /11/ 2008 Gadoversetamide g/ml Optimark 0.5mmol/ml(20ml) INJE /ml Sabbagh Mallinckrodt /11/ Tasigna Cubicin 14 /12/ 2008 CAPS 200 Nilotinib 200 Daptomycin 350 Powder 350 Roche Pharma novartis

4 50 24 /12/ 2008 Rasilez tab TAB 300 Aliskiren 300 novartis 51 Januvia 31 /12/ 2008 TAB 100 Sitagliptin 100 Adatco Merck &.Inc /1/ 2009 Valganciclovir 450 F.Hoffmann La- Valcyte F.C.Tablet TAB 450 Roche 53 8 /4/ 2009 Tarceva F.C.Tablet TAB 100 Erlotinib 100 roche 54 5 /5/ 2009 Suleiman Tannous & Tykerb TAB 250 Lapatinib 250 Sons. Ltd Glaxo Group Ltd 55 7 /12/ 2009 Rivaroxaban Xarelto TAB 10 Micronized 10 Khoury Bayer Health Care 56 Firmagon vial 20/6/2010 Powder& solvent for Degarelix solution for inj 80 Petra drug store Ferring 28/11/2010 Solution for Sugammadex 57 Bridion injection 100/ml Adatco N.V Organon 10/2/2011 Jordan 58 Valdoxan Agomelatine. tab 25 Servier 59 13/11/2011 capsules Jordan Onbrez Breezhaler containing a powder for 150 and 300 Indacaterol maleate Novartis inhalation micrograms 60 Victoza 28/11/2011 Solution for inj in PFP 6 /ml Liraglutide Khoury Novo Nordisk

5 61 62 Multaq F.C tab IBD: 31/7/2009 Submission date:14/10/2010 Prolia. IBD: 26/5/2010 Submission date:16/12/ Onglyza IBD: 31/7/2009 Submission date:27/1/ /6/2012 4/3/2012 F.C tab Solution for inj in PFP /ml 17/5/2012 Tab 5 Dronedarone Denosumab Saxagliptin Ulfa Adatco drug store Sanofi Aventis Aen Astrazeneca Gilenya 64 IBD: 17/8/2010 Submission date:28/4/ Brilinta IBD: 3/12/2010 Submission date:12/5/2011 Jevtana vial 66 IBD: 17/8/2010 Submission date:28/4/ Zytiga IBD: 28/4/2011 Submission date:26/1/ Brinavess IBD: 9/2010 Submission date:27/10/ /4/ /7/ /1/ /11/ /3/2013 Cap 0.5 Fingolimod Tab 90 Ticagrelor Novartis Astrazeneca conc. & solvent for infusion. 60 Cabazitaxel Ulfa Sanofi Tablet 250 Abitraterone Acetate Telegraph Janssen-Cilag Inernational ncentrate for Solution for infusion 20/ml Vernakalant Hcl Adatco drug store MSD LTD

6 69 Trajenta IBD: 20/5/2011 Submission date: 6/11/ Incivo IBD: 23/5/2011 Submission date:13/3/ Victrelis IBD : 13/5/2011 Submission date : 19/2/ Stivarga IBD : 27/9/2012 Submission date : 14/8/2013 mmission decision date : 2/4/ Eylea IBD : 18/11/2011 Submission date : 4/4/2013 mmission decision date : 21/5/ Signifor IBD : 24/4/2012 Submission date : 20/5/2013 mmission decision date : 5/11/2014 9/10/ /10/ /7/ /5/2014 6/7/2014 8/2/2015 tablet 5 Linagliptin Arab drug store (shqer) tablet 375 Telaprevir Ninos drug store Hard capsule 200 Boceprevir Adatco drug store tablet 40 Regorafinib Khori drug store Solution for injection 40 /ml aflibercept Khori drug store Solution for injection 0.3 /ml 0.6 /ml 0.9/ml Pasireotide Dispartate Boehringer Ingelheim International GmbH,Ingelheim am Rhein Janssen-Cilag international MSD/Ltd UK Bayer Pharma A G / Germany Bayer Pharma A G / Germany /Switzerland

7 75 Zelboraf IBD : 17/8/2011 Submission date : 14/10/2012 mmission decision date : 19/11/ Lyxumia IBD : 7/1/2013 Submission Date : 28/11/2013 mmission decision date : 5/8/ Exviera IBD : 15/1/2015 Submission Date : 10/2/2015 mmission decision date : 12/8/ Viekirax IBD : 15/1/2015 Submission Date : 10/2/2015 mmission decision date : 19/8/ Giotrif IBD : 2/7/2013 Submission Date : 29/9/2014 mmission decision date : 16/9/2015 4/2/2015 9/12/ /8/ /9/ /11/2015 tablet 240 Vemurafenib Pre-filled Pen 10mcg 20mcg 10&20 mcg Lixisenatide Ulfa Tablet 250 Dasabuvir Tablet Ombitasvir Paritaprevir Ritonavir tablet 20 Afatinib Abu sheikha drug store Abu sheikha drug store Arab drug store (shqer) F.hoffman la-roche /Switzerland Sanofi avemtis groupe/ France Abbvie limited / UK Abbvie limited / UK Boehringer ingelheim international / Germany Last reviewed in 12/12015 في حال الحاجة لالعتراض على محتويات القائمة ارجو ارسال كتاب رسمي لقسم التسجيل.

New chemical Entity Registered ( )

New chemical Entity Registered ( ) N# Product Name Registration Date )ل ف ) 1 Dosage form Strength Active Ingredient Drug Store Marketing Authorization Holder 1 pegus 25/5/2005 tab 200 Ribavarin Shawi Roche 2 Velcade 7/7/2005 vial 3.5 bortezomib

More information

New chemical Entity Registered ( )

New chemical Entity Registered ( ) N# Product Name Registration Date )ل ف ) 1 Dosage form Strength Active Ingredient Marketing Authorization Holder 1 pegus 25/5/2005 tab 200 Ribavarin Shawi Roche 2 Velcade 7/7/2005 vial 3.5 bortezomib mina

More information

TABLE OF CONTENTS 1 Table of Contents 2 Introduction 3 Key Marketed Products

TABLE OF CONTENTS 1 Table of Contents 2 Introduction 3 Key Marketed Products TABLE OF CONTENTS 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Epidemiology 2.2 Symptoms 2.3 Etiology 2.4 Pathophysiology 2.5 Co-morbidities and Complications 2.6 Classification

More information

PBS Growth. The changing composition of the PBS. PBS Top 10 drugs in transition. Shifting sands for industry as generic volume soars

PBS Growth. The changing composition of the PBS. PBS Top 10 drugs in transition. Shifting sands for industry as generic volume soars PBS Growth The changing composition of the PBS PBS Top 10 drugs in transition Shifting sands for industry as generic volume soars The under co-payment market PBS Update 2014-15 Growth in PBS spending was

More information

New Exception Status Benefits

New Exception Status Benefits AUGUST 2017 Nova Scotia Formulary Updates New Exception Status Benefits Forxiga (dapagliflozin) Xigduo (dapagliflozin and metformin hydrochloride) Criteria Update: Antipsychotic Medications Abilify (aripiprazole)

More information

FARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)

FARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin) Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your

More information

Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015

Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015 J0129 Injection, abatacept (Orencia ), 10 J0178 Injection, aflibercept (Eylea ), 1 J0256 J0257 J0585 J0586 J0587 J0588 J0597 J0641 J0717 J0800 Injection, alpha 1-proteinase inhibitor, human (Aralast NP,

More information

THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES

THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016 There is growing distrust of pharma in light of several recent and dramatic

More information

Current and future market dynamics overview

Current and future market dynamics overview OVERVIEW Catalyst Summary EXECUTIVE SUMMARY Strategic scoping and focus Datamonitor key findings Related reports MARKET DEFINITION Published diabetes reports Market definition for antidiabetic drugs Forecast

More information

NEW MEDICINE APPLICATIONS BROUGHT TO THE BORDERS FORMULARY COMMITTEE (BFC) AND AREA DRUG & THERAPEUTICS COMMITTEE (ADTC) 2015/16

NEW MEDICINE APPLICATIONS BROUGHT TO THE BORDERS FORMULARY COMMITTEE (BFC) AND AREA DRUG & THERAPEUTICS COMMITTEE (ADTC) 2015/16 New Medicine Product/Device Endorsement Categories NEW MEDICINE APPLICATIONS BROUGHT TO THE BORDERS FORMULARY COMMITTEE (BFC) AND AREA DRUG & THERAPEUTICS COMMITTEE (ADTC) 2015/16 A B C D E F recommended

More information

PORTFOLIO MADE WITH CARE. FDF Generics Chlorhexidine API

PORTFOLIO MADE WITH CARE. FDF Generics Chlorhexidine API PORTFOLIO MADE WITH CARE FDF Generics Chlorhexidine API MADE WITH CARE Generics API LONG-TERM WORLDWIDE EXPERIENCE FDF HPAPI Intermediates API SEAMLESS DEVELOPMENT FDF FIRST TO MARKET GENERICS FDF MOLECULE

More information

Iraq NDI Iraq 04-J India 05-AH France Famar Lyon France 05-D UNITED ARAB EMIRATES. Iraqi Biocon Limited Indian 06-AA0-001

Iraq NDI Iraq 04-J India 05-AH France Famar Lyon France 05-D UNITED ARAB EMIRATES. Iraqi Biocon Limited Indian 06-AA0-001 nam origmanufacturer nammanufacturer National code Mousel Scientific Iraq NDI Iraq 04-J00-042 Sandoz GmbH Austria for Sandoz GmbH by Sandoz Ilac Sanayi ve India 05-AH0-040 France Famar Lyon France 05-D00-024

More information

Applications received for new investments since 1 November 2008

Applications received for new investments since 1 November 2008 Applications received for new investments since 1 November 2008 Details of Funding Applications received are published on PHARMAC s website, in accordance with the Terms of Reference for the Pharmacology

More information

CONTACT POLPHARMA GROUP POLPHARMA B2B

CONTACT POLPHARMA GROUP POLPHARMA B2B DOSSIER FDFLIST Product name Pharmaceutical form Strength Reference Therapeutic class ALIMENTARY TRACT & METABOLISM 1. Esomeprazole sodium or injection 40 mg Nexium / AstraZeneca Antiulcerant 2. Omeprazole

More information

NICE TA Adherence Check List

NICE TA Adherence Check List NICE TA Adherence Check List KEY NICE TA PAS Not Terminated Indication Technology Appraisal carried out by the National Institute of Clinical Excellence - It is the process by which new and existing drugs

More information

STEP THERAPY CRITERIA

STEP THERAPY CRITERIA CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)

More information

PRAC recommendations on signals

PRAC recommendations on signals 18 May 2017 EMA/PRAC/252869/2017 Pharmacovigilance Risk Assessment Committee (PRAC) Adopted at the 2-5 May 2017 PRAC meeting This document provides an overview of the recommendations adopted by the Pharmacovigilance

More information

2014 DTC National Advertising Awards Finalists

2014 DTC National Advertising Awards Finalists 2014 DTC National Advertising Awards Finalists All Gold, Silver, and Bronze winners will be announced at the DTC National Advertising Awards Dinner on April 23. Each therapeutic category winner from Television,

More information

NICE TA Adherence Check list April Drug Indication NICE Approval Release Date

NICE TA Adherence Check list April Drug Indication NICE Approval Release Date NICE TA Adherence Check list April 2014 Drug Indication NICE Approval Release Date Bortezomib Multiple myeloma (induction therapy) Afatinib Rituximab Pixantrone Aflibercept Teriflunomide Fluocinolone acetonide

More information

US pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health

US pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health US pharmaceutical market: trends, issues, forecast Doug Long Vice President Industry Relations IMS Health 2006 Strategic management review The World Pharmaceutical Market All reproduction rights, quotations,

More information

Quality of medicines in Portugal: a retrospective review of medicine recalls ( ) Ana Teresa Reis Bruna Berardo Rui Loureiro

Quality of medicines in Portugal: a retrospective review of medicine recalls ( ) Ana Teresa Reis Bruna Berardo Rui Loureiro Quality of medicines in Portugal: a retrospective review of medicine recalls (2005-2015) Ana Teresa Reis Bruna Berardo Rui Loureiro Introduction Human medicines Cosmetics Veterinary medicines Medical devices

More information

Deaths Hospitalizations Company. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Janssen Pharmaceuticals

Deaths Hospitalizations Company. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Janssen Pharmaceuticals Takeaways: Diabetes Drug Investigation From: BSardi@aol.com Sent: Mon, Dec 22, 2014 at 10:51 am To: Cc: gemcap2@reagan.com martie.whittekin@verizon.net, katjames008@gmail.com clip_image002.jpg (64.5 KB)

More information

Navigating the New Options for the Management of Type 2 Diabetes

Navigating the New Options for the Management of Type 2 Diabetes Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of

More information

NEW MEDICINE APPLICATIONS BROUGHT TO THE BORDERS FORMULARY COMMITTEE (BFC) AND AREA DRUG & THERAPEUTICS COMMITTEE (ADTC) 2015/16

NEW MEDICINE APPLICATIONS BROUGHT TO THE BORDERS FORMULARY COMMITTEE (BFC) AND AREA DRUG & THERAPEUTICS COMMITTEE (ADTC) 2015/16 New Medicine Product/Device Endorsement Categories NEW MEDICINE APPLICATIONS BROUGHT TO THE BORDERS FORMULARY COMMITTEE (BFC) AND AREA DRUG & THERAPEUTICS COMMITTEE (ADTC) 2015/16 A B C D E F recommended

More information

ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced

ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced Class Medicine Name Nappi Strength Form Size Route Abiraterone Acetate ZYTIGA

More information

Drugs in Focus The early bird catches the worm! Selection of novel, still patented APIs for development activities in patent free countries

Drugs in Focus The early bird catches the worm! Selection of novel, still patented APIs for development activities in patent free countries Drugs in Focus The early bird catches the worm! Selection of novel, still patented APIs for development activities in patent free countries Searching for patent circumventing manufacturing processes, polymorphic

More information

July 2014 PBAC OUTCOMES - "1 st time" decisions not to recommend. Drug Type and Use. Drug Name, form(s), strength(s), Sponsor,

July 2014 PBAC OUTCOMES - 1 st time decisions not to recommend. Drug Type and Use. Drug Name, form(s), strength(s), Sponsor, July 2014 PBAC OUTCOMES - "1 st time" decisions not to recommend Drug Name, form(s), ABIRATERONE, tablet, 250 mg, Zytiga Janssen-Cilag Pty Ltd Change to listing Prostate Cancer Section 85 Authority required

More information

AVAILABLE DOSSIERS. Product name Pharmaceutical form Strength Reference Therapeutic class

AVAILABLE DOSSIERS. Product name Pharmaceutical form Strength Reference Therapeutic class DOSSIER LIST AVAILABLE DOSSIERS Product name Pharmaceutical form Strength Reference Therapeutic class ALIMENTARY TRACT & METABOLISM Esomeprazole sodium Omeprazole sodium injection / 40 mg Nexium / AstraZeneca

More information

Legal Supplement Part B Vol. 57, No. 6 18th January, NOTIFICATION NOTICE OF APPROVAL IN RESPECT OF NEW DRUGS

Legal Supplement Part B Vol. 57, No. 6 18th January, NOTIFICATION NOTICE OF APPROVAL IN RESPECT OF NEW DRUGS Legal Supplement Part B Vol. 57, No. 6 18th January, 2018 11 LEGAL NOTICE NO. 5 REPUBLIC OF TRINIDAD AND TOBAGO FOOD AND DRUGS ACT, CHAP. 30:01 NOTIFICATION NOTICE OF APPROVAL IN RESPECT OF NEW DRUGS ISSUED

More information

PRAC recommendations on signals

PRAC recommendations on signals 14 December 2017 EMA/PRAC/610978/2017 Pharmacovigilance Risk Assessment Committee (PRAC) Adopted at the 27-30 November 2017 PRAC meeting This document provides an overview of the recommendations adopted

More information

INCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS

INCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS INCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS PHM162A February 2015 Kim Lawson Project Analyst ISBN: 1-62296-047-5 BCC Research 49 Walnut Park, Building 2 Wellesley, MA

More information

Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List

Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List Code Drug Name Effective and/or Term Date J0129 Injection, abatacept (Orencia ), 10 mg J0178 Injection, aflibercept (Eylea

More information

Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018

Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018 Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018 Objectives For each drug class: Identify the overall place in therapy Explain the mechanism of action

More information

Pharmaceuticals and Medical Devices. Safety Information

Pharmaceuticals and Medical Devices. Safety Information Safety Information No. 243 January 2008 Table of Contents 1. Revision of PRECAUTIONS (No. 193) 3 Flurbiprofen (oral dosage form) and 6 others 2. List of products subject to Early Post-marketing Phase Vigilance

More information

DOSSIER LIST. tlo_seledyn.pdf :38:01 CMY K CM MY CY

DOSSIER LIST. tlo_seledyn.pdf :38:01 CMY K CM MY CY tlo_seledyn.pdf 1 22.08.2017 14:38:01 C M Y CM MY CY CMY K DOSSIER LIST AVAILABLE DOSSIERS THERAPEUTIC CLASS / MAIN INDICATION LACTOSE FREE ZONE IV CPP FEASIBILITY ALIMENTARY TRACT & METABOLISM 1. Esomeprazole

More information

A 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper)

A 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper) A 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper) Approved Kinase Inhibitors September 2014 Sponsored by PamGene www.pamgene.com The Kinase Activity Profiling

More information

Medicines availability short-term supply issues Last updated 01/05/18

Medicines availability short-term supply issues Last updated 01/05/18 Short-term supply issues This resource includes availability information on medicines that are reported to have supply issues, with next expected availability within the next three months. This list is

More information

BRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH

BRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH Insulin Initiation BRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH Disclosures In the past 12 months, I have received speakers honoraria from AstraZeneca, Boehringer Ingelheim,

More information

John Ansell President, John Ansell Consultancy Thame, UK

John Ansell President, John Ansell Consultancy Thame, UK Rutgers University Monday 29 September 2014 Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva 1

More information

Our Values. Quality Intelligent efforts in everyday practice. Innovation Change that unlocks new value. Performance Passion for results

Our Values. Quality Intelligent efforts in everyday practice. Innovation Change that unlocks new value. Performance Passion for results Product Guide Our Values 1 Innovation Change that unlocks new value Our continuous progress and growth depends on the investments we make on scientific research for new medicines and technologies. Innovation

More information

ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS

ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS PHM119B September 2016 Anuj Pathak Project Analyst ISBN: 1-62296-345-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA

More information

Very Practical Tips for Managing Type 2 Diabetes

Very Practical Tips for Managing Type 2 Diabetes Very Practical Tips for Managing Type 2 Diabetes Jean-François Yale, MD, FRCPC McGill University Health Centre, Montreal, Canada Jean-francois.yale@mcgill.ca www.dryale.ca OBJECTIVES DISCLOSURES The participant

More information

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP)

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22 July 2011 EMA/CHMP/557552/2011 corr* 1 Press Office Press release Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 July 2011 Positive opinions for new medicines

More information

Pharmaceuticals and Medical Devices. Safety Information

Pharmaceuticals and Medical Devices. Safety Information Safety Information No. 244 February 2008 Table of Contents 1. Revision of PRECAUTIONS (No. 194) GEM-Premier 3000 PAK and 10 others 3 2. List of products subject to Early Post-marketing Phase Vigilance

More information

PRAC recommendations on signals

PRAC recommendations on signals 5 November 2013 EMA/PRAC/625262/2013 Pharmacovigilance Risk Assessment Committee Adopted at the PRAC meeting of 7-10 October 2013 This document provides an overview of the recommendations adopted by the

More information

MABCAMPATH mg 3 INJ GENZYME BIOPHARMACEUTICALS. MABCAMPBATH mg 3 INJ GENZYME BIOPHARMACEUTICALS

MABCAMPATH mg 3 INJ GENZYME BIOPHARMACEUTICALS. MABCAMPBATH mg 3 INJ GENZYME BIOPHARMACEUTICALS ICON Formulary - November 2016 Class Medicine Name Nappi Strength Form Size Route Manufacturer Abiraterone Acetate ZYTIGA 250 720690001 250 mg 120 ORAL JANSSEN PHARMACEUTICALS Aldesleukin CHIRON IL-2 18

More information

CRITERIA Trial of two generic formulary products from the following: atomoxetine or ADHD stimulant medication.

CRITERIA Trial of two generic formulary products from the following: atomoxetine or ADHD stimulant medication. ADHD STIMULANTS ATOMOXETINE HCL, DEXEDRINE 10 MG TABLET, DEXEDRINE 5 MG TABLET, DEXMETHYLPHENIDATE HCL, DEXMETHYLPHENIDATE HCL ER, DEXTROAMPHETAMINE 10 MG TAB, DEXTROAMPHETAMINE 5 MG TAB, DEXTROAMPHETAMINE

More information

List of Designated High-Cost Drugs

List of Designated High-Cost Drugs List of Designated High-Cost Drugs UPDATED APRIL 25, 2018 For details on the High-Cost Drug policy, see Section 5.8 of the PharmaCare Policy Manual. Recent updates appear in red. Deletions are listed at

More information

Genetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School

Genetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School Genetics in Cancer Therapy Raju Kucherlapati, Ph.D. Harvard Medical School RK Financial interests I do not intend to discuss an off-label use of a product during this activity AVEO Pharmaceuticals KEW

More information

This article is a CME/CE certified activity. To earn credit for this activity visit:

This article is a CME/CE certified activity. To earn credit for this activity visit: Novel Perspectives on Type 2 Diabetes: Traditional and Emerging Therapies and the Potential Role of the Kidneys This article is a CME/CE certified activity. To earn credit for this activity visit: www.medscape.org/lecture/t2dm-therapies

More information

Official Journal of the European Union C 401/3

Official Journal of the European Union C 401/3 28.12.2012 Official Journal of the European Union C 401/3 Summary of European Union s on marketing authorisations in respect of medicinal s from 1 November 2012 to 30 November 2012 (Published pursuant

More information

Name of firm/applicant

Name of firm/applicant Recommendation:- The 18 th Subject Expert Committee (Oncology & Hematology) deliberated the proposals on 04.07.2014 and recommended the following:- Agenda no. Drug name Name of firm/applicant Recommendations

More information

Drugs reviewed by the SMC in September 2012 ADTC UPDATES ON DRUGS REVIEWED BY THE SMC

Drugs reviewed by the SMC in September 2012 ADTC UPDATES ON DRUGS REVIEWED BY THE SMC Area Drug and Therapeutics Committee Prescribing Supplement No 62 In this issue Drugs reviewed by the SMC in September 2012 ADTC UPDATES ON DRUGS REVIEWED BY THE SMC The following new drugs have been reviewed

More information

SUNY Binghamton, B.S. Biochemistry, 5/80 SUNY Downstate Medical Center, M.D., 6/84

SUNY Binghamton, B.S. Biochemistry, 5/80 SUNY Downstate Medical Center, M.D., 6/84 CURRICULUM VITAE RUSSELL D'AMBRA, M.D. July 2014 North Shore Diabetes & Endocrine Associates 3003 New Hyde Park Road Suite 201 New Hyde Park, New York 11042 516-327-0850 EDUCATION: POST-GRADUATE TRAINING:

More information

LIST OF DRUGS DURING 2004

LIST OF DRUGS DURING 2004 LIST OF DRUGS DURING 2004 S.NO Name Of Drug Pharmacological Classification Date of Approval 188 Dutasteride For BPH 16-02-2004 189 Gefitinib Anti-cancer 17-02-2004 190 Imidapril Anti-hypertensive 23-02-2004

More information

April 2015 May SMC RECOMMENDED MEDICINES FOR USE Recommended for use within NHS Scotland April 2015 May 2015 Date SMC SMC Drug Name

April 2015 May SMC RECOMMENDED MEDICINES FOR USE Recommended for use within NHS Scotland April 2015 May 2015 Date SMC SMC Drug Name April 2015 May 2015 RECOMMENDED MEDICINES FOR USE Recommended for use within NHS Scotland April 2015 May 2015 Date Advice Published aclidinium / formoterol fumarate dehydrate (Duaklir Genuair) Almirall

More information

SUPPLEMENTARY DATA. Telediab Study Group :

SUPPLEMENTARY DATA. Telediab Study Group : Telediab Study Group : Guillaume Charpentier, MD, Department of Diabetes, Sud-Francilien Hospital, Corbeil-Essonnes, France Centre d Études et de Recherches pour l Intensification du Traitement du Diabète

More information

NEW PATENTED MEDICINES REPORTED TO PMPRB 2011 (UPDATE AS OF NOVEMBER 30, HIGHLIGHTED)

NEW PATENTED MEDICINES REPORTED TO PMPRB 2011 (UPDATE AS OF NOVEMBER 30, HIGHLIGHTED) HUMAN DRUGS NEW PATENTED MEDICINES REPORTED TO PMPRB 2011 COMPANY BRAND NAME CHEMICAL NAME DIN THERAPEUTIC USE DATE OF FIRST SALE Abbott Laboratories Limited Norvir 100 mg/tablet ritonavir 02357593 HIV

More information

How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study

How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study RESEARCH PAPER How Safe and Are First-in-Class Drugs Approved by Health Canada: A Cohort Study L innocuité et l aspect innovant des nouvelles classes de médicaments approuvés par Santé Canada : une étude

More information

1 17 ACITRETIN 10MG CAP 20, ,000 14,000 4, ACITRETIN 25MG CAP 50, ,000 35,000 10,000

1 17 ACITRETIN 10MG CAP 20, ,000 14,000 4, ACITRETIN 25MG CAP 50, ,000 35,000 10,000 ردیف کد ژنریک نام ژنریک مبلغ پوشش وزارت بهداشت مبلغ پوشش بیمه مبلغ پرداخت بیمار درصد پرداخت بیمار قیمت اعالمی وزارت بهداشت نام تجاری 1 17 ACITRETIN 10MG CAP 20,000 10.0 2,000 14,000 4,000 2 18 ACITRETIN

More information

Update on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015

Update on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015 Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages

More information

Physician Drug Reference Chart for Diabetes Antidiabetic Medications

Physician Drug Reference Chart for Diabetes Antidiabetic Medications Drug Class Compound Brand Name Mechanism of Action Advantages Disadvantages Alpha-glucosidase inhibitors Medium Cost by Bayer Healthcare, Pfizer, Takeda Research Acarbose Miglitol Voglibose Precose Glyset

More information

Oregon Health Plan prescription benefit updates

Oregon Health Plan prescription benefit updates Oregon Health Plan prescription benefit updates EOCCO s prescription program is a pharmacy benefit that offers members a choice of safe and effective medication treatments. The program also helps you save

More information

PRAC recommendations on signals

PRAC recommendations on signals 15 September 2016 EMA/PRAC/551805/2016 Corr 1 Pharmacovigilance Risk Assessment Committee (PRAC) Adopted at the PRAC meeting of 30 August-2 September 2016 This document provides an overview of the recommendations

More information

Prescription benefit updates Large group

Prescription benefit updates Large group Prescription benefit updates Large group Moda Health s prescription program is a pharmacy benefit that offers members a choice of safe effective medication treatments. The program also helps you save money

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Hwang TJ, Bourgeois FT, Seeger JD. Drug safety in the digital

More information

Pharmaceuticals and Medical Devices Safety Information

Pharmaceuticals and Medical Devices Safety Information Pharmaceuticals and Medical Devices Safety Information No. 248 July 2008 Table of Contents 1. Revision of PRECAUTIONS (No. 198) (1) Bepridil Hydrochloride (and 1 other) 3 2. List of products subject to

More information

Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2016 Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2016 Recurrent Glioblastoma Multiforme (GBM) - Pipeline

More information

Table 1. New drugs approved by the US Food and Drug Administration (FDA): December 13, 2014 through January 18, 2015

Table 1. New drugs approved by the US Food and Drug Administration (FDA): December 13, 2014 through January 18, 2015 Hosp Pharm 2015;50(3):238 242 2015 Thomas Land Publishers, Inc. www.hospital-pharmacy.com doi: 10.1310/hpj5003-238 Current FDA-Related Drug Information Approvals, Submission, and Important Labeling Changes

More information

How to Fight Diabetes and Win. Diabetes. Medications

How to Fight Diabetes and Win. Diabetes. Medications How to Fight Diabetes and Win Diabetes Medications MEDICATIONS FOR DIABETES According to the American Diabetes Association, 85% of adults diagnosed with diabetes take insulin and/or oral medication to

More information

Brand companies identified in CPS or whether generic versions are available

Brand companies identified in CPS or whether generic versions are available Appendix 3: Guideline-level data on recommended drugs and guideline-affiliated organizations Clinical practice guideline ID # Most recent review or publish date CPS year 5 2013 2013 7 2013 2013 18 2013

More information

Country of Supplying Company. Supplying Company. Anfarm Hellas S.A. Greece

Country of Supplying Company. Supplying Company. Anfarm Hellas S.A. Greece 01-AA0-006 01-B00-016 Digoxin 250 mcg/ml inj (2ml) Ampoule Spironolactone 25mg Digoxin/Anfar m Spironoam 25 tab Greece Greece 6 8322 4.5 $ Iraq 10 89122 500 ID سامراء Iraq سامراء 02-B00-008 Hyocine butylbromide

More information

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP)

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25 June 2010 corr. 1 Press Office Press release Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 June 2010 Positive opinions for new medicines adopted The Committee

More information

Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards

Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards Jeffrey M. Bockman, PhD Vice President Defined Health 24 th Annual Cancer Progress Conference March 4 th 5 th, 2014 March 4 th 5 th,

More information

REGISTER OF INTERESTS SIGN guideline 154: Pharmacological management of glycaemic control in people with type 2 diabetes Published: 29 November 2017

REGISTER OF INTERESTS SIGN guideline 154: Pharmacological management of glycaemic control in people with type 2 diabetes Published: 29 November 2017 CHAIR John Petrie, Professor of Diabetic Medicine Financial Non-financial Non-personal Last updated Specific Non-Specific Specific Non- Specific Professor of Diabetic Medicine, University of Glasgow Academic.

More information

NIT165 - RECEIVED PRICE DETAIL. Quantity in Unit/SKU. Company Name. Abbott Healthcare Private Ltd.

NIT165 - RECEIVED PRICE DETAIL. Quantity in Unit/SKU. Company Name. Abbott Healthcare Private Ltd. S C I Total 1 120003 Acenocoumarol/Nicoumalone Tablet 2 mg 10 x 10 15,000 223.33 6 6 26.7996 250.1296 2 120016 Amitriptyle Tab. IP - 25 mg 10X10 4,120 Micron Pharmaceuticals 27.9 12 3.348 31.248 3 120030

More information

NATIVA GROUP. Inspired by Innovation and Technology

NATIVA GROUP. Inspired by Innovation and Technology NATIVA GROUP Inspired by Innovation and Technology INNOVATION & TECHNOLOGY IS OUR PASSION Nativa is a leading group of pharmaceutical companies in Russia. It develops and produces worldclass complex medicines

More information

Aetna Better Health of Illinois Medicaid Formulary Updates

Aetna Better Health of Illinois Medicaid Formulary Updates October 2017 o DOXYLAMINE SUCCINATE 25mg-QL o DULOXETINE CAP 40MG DR-QL o GUANFACIN ER TABS (all strengths)-ql o TOBRAMYCIN NEBU SOLUTION- PA August 2017 Aetna Better Health of Illinois Medicaid 2017 Formulary

More information

SASKATCHEWAN FORMULARY COMMITTEE UPDATE BULLETIN TO THE 55th EDITION OF THE SASKATCHEWAN FORMULARY

SASKATCHEWAN FORMULARY COMMITTEE UPDATE BULLETIN TO THE 55th EDITION OF THE SASKATCHEWAN FORMULARY Saskatchewan Health Drug Plan and Extended Benefits Branch April 2006 Bulletin #106 ISSN 0708-3246 SASKATCHEWAN FORMULARY COMMITTEE UPDATE BULLETIN TO THE 55th EDITION OF THE SASKATCHEWAN FORMULARY All

More information

Status of Import License (Form 10) of Recombinant Products, Human and Veterinary Vaccines issued from 01/03/2016 to 29/04/2016

Status of Import License (Form 10) of Recombinant Products, Human and Veterinary Vaccines issued from 01/03/2016 to 29/04/2016 1. M/s LG Life Sciences India Pvt. Ltd.,Basement Commercial SCO No. 321, Sector-29, Gurgaon, India 2. M/s Eli Lilly and Co (I) Pvt. Ltd., Bldg. No. 14, Gala No. 1 to 4, 1 st Fl, Arihant Comm. Complex,

More information

A Clinical Context Report

A Clinical Context Report Stroke Prevention in Atrial Fibrillation An Expert Commentary With Kenneth W. Mahaffey, MD A Clinical Context Report Stroke Prevention in Atrial Fibrillation Expert Commentary Jointly Sponsored by: and

More information

Innovative Products Available. OTC Products Available

Innovative Products Available. OTC Products Available Innovative Products Benfotiamine film-coated tablets 150 mg Cholecalciferol film-coated tablets 22400 I.U. Diltiazem rectal ointment 2% Agents for Treatment of Hemorrhoids and Fissures Blood and Blood

More information

What the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin

What the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team

More information

TN Cover Rx Tennessee CoverRx MAC Price Change List As of: 04/26/2018

TN Cover Rx Tennessee CoverRx MAC Price Change List As of: 04/26/2018 1 Tennessee CoverRx List Run : 04/26/18 Dosage Form amiodarone HCl 200 MG TABLET ORAL 04/25/2018 0.16102 0.14405 11.8 hydralazine HCl 100 MG TABLET ORAL 04/25/2015 0.11390 0.10854 4.9 hydralazine HCl 25

More information

Orphanet Rep rts Series

Orphanet Rep rts Series List of marketing authorised Orphan Drugs in Europe January 2008 Orphan drugs by tradename in alphabetical order Orphan drugs by decreasing of marketing authorisation Orphan drugs in therapeutic areas

More information

MEDICINES CONTROL COUNCIL

MEDICINES CONTROL COUNCIL Notification of of Medicines MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965)

More information

Area Drug and Therapeutics Committee Prescribing Supplement No 22 June 2008

Area Drug and Therapeutics Committee Prescribing Supplement No 22 June 2008 Area Drug and Therapeutics Committee Prescribing Supplement No 22 In this issue Drugs currently being considered by SMC advice due on 09 ADTC decisions carried over from the previous bulletin in February

More information

Role of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney

Role of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney Role of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney Consultant Thoracic Pathologist Royal Liverpool University Hospital Disclosure JRG is a paid advisor

More information

GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA. N$2.00 WINDHOEK - 3 June 2011 No. 4726

GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA. N$2.00 WINDHOEK - 3 June 2011 No. 4726 GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA N$2.00 WINDHOEK - 3 June 2011 No. 4726 CONTENTS Page GOVERNMENT NOTICE No. 71 Medicines and Related Substances Control Act, 2003: Registration of certain medicines...

More information

WellCare s South Carolina Preferred Drug List Update

WellCare s South Carolina Preferred Drug List Update WellCare s South Carolina Preferred Drug List Update This is a list of changes to our preferred drug list. These are a result of the latest WellCare Pharmacy & Therapeutics meeting held on 09/03/2015.

More information

CHAPTER THREE: INDUSTRY OVERVIEW... 6 HISTORICAL PERSPECTIVE OF THE MENTAL HEALTH INDUSTRY... 6 HISTORICAL PERSPECTIVE OF THE (CONTINUED)...

CHAPTER THREE: INDUSTRY OVERVIEW... 6 HISTORICAL PERSPECTIVE OF THE MENTAL HEALTH INDUSTRY... 6 HISTORICAL PERSPECTIVE OF THE (CONTINUED)... CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR STUDY... 1 SCOPE OF STUDY... 1 METHODOLOGY AND INFORMATION SOURCES... 2 ANALYST CREDENTIALS... 2 RELATED BCC REPORTS... 2 DISCLAIMER...

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Self Administered Oncology Agents Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Self Administered Oncology Agents Prime Therapeutics will review Prior

More information

in patients with diabetes, nephropathy and/or chronic kidney disease Summary of recommendations July 2017

in patients with diabetes, nephropathy and/or chronic kidney disease Summary of recommendations July 2017 Association of British Clinical Diabetologists (ABCD) and Renal Association clinical guidelines: Hypertension management and reninangiotensin-aldosterone system blockade in patients with diabetes, nephropathy

More information

(Poster presented on Sunday 05 March, 08:50 08:55; 2017 AAD Meeting, Orlando, Florida, USA)

(Poster presented on Sunday 05 March, 08:50 08:55; 2017 AAD Meeting, Orlando, Florida, USA) Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis: Patient-Reported Outcomes in the Corrona Psoriasis Registry AB Gottlieb, B Strober, 2 AW Armstrong, 3 JD Greenberg, 4,5 C Karki, 4

More information

BRIC DIABETES DRUGS MARKET

BRIC DIABETES DRUGS MARKET BRIC DIABETES DRUGS MARKET R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p o r t s A b o u t M a r k e t s a n d M a

More information

MEDICINES CONTROL COUNCIL

MEDICINES CONTROL COUNCIL MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 07/3.1.2.2/23 NOVARTIS SA

More information

Du gusts is megl che one. Edoardo Mannucci

Du gusts is megl che one. Edoardo Mannucci Du gusts is megl che one Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer Ingelheim, Eli

More information

2018 CareOregon Advantage Part D Formulary Changes

2018 CareOregon Advantage Part D Formulary Changes 2018 CareOregon Advantage Part D Formulary Changes Abbreviations: AGE = Age Restriction; PA = Prior Authorization Required; QL = Quantity Limit; ST = Step Therapy Required; LD = Limited Distribution; BvD

More information